After testing the samples of the cream-based ointment, NML has ruled that the medication does not comply with the same standard as that of its gel-based counterpart that had earned a reputation for its effectiveness.

The Department of Drug Administration, the governing body of NML, mentions in its report that the cream does not meet the government specifications— a yellowish or colourless semi-transparent gel filled in printed collapsible aluminium tubes. The entire batch of the medication procured this time is cream-based, white and semi-solid, and the expiration date on the sample ointments were found tampered, DDA has said. According to medical experts, cream-based ointment can enter the skin, and might cause infection unlike gel that creates a shield on the skin, keeping the freshly cut umbilical cord safe from infections.

The government states that sepsis in the first week or two of life is a major cause of newborn deaths and the Chlorhexidine gel has helped in reducing the mortality. The Logistics Management Division (LMD) of the Department of Health Services on April 21 had sent the cream samples to the DDA for lab analysis to determine if it could be used. After testing the samples, NML on June 18 had written to the LMD, warning that the batch number CH601of the ointment did not comply with the set standards.  

Dr Bhim Tinkari, director of the LMD, said the case is currently being investigated by the Commission for Investigation of Abuse of Authority.

Spokesperson at the CIAA Shreedhar Sapkota denied to share information regarding the investigation in progress, but a source at the department of health said that the anti-graft has been holding consultations with health officials.